BursteinHJ, 2005.The distinctive nature of HER2-positive breast cancers,New Engl J Med 353 1652 -4
MitriZ,ConstantineT,O'Regan R. The, 2012.HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy,Chemother Res Pract 743193 -
AndersonWF,RosenbergPS,KatkiHA, dju093.Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer,J Natl Cancer Inst Monogr 106 -
CuriglianoG,VialeG,BagnardiV,FumagalliL,LocatelliM,RotmenszN, 2009.Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer,J Clin Oncol 27 5693 -9
Gonzalez-AnguloAM,LittonJK,BroglioKR,Meric-BernstamF,RakkhitR,CardosoF, 2009.High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller,J Clin Oncol 27 5700 -6
RouanetP,RogerP,RousseauE,ThibaultS,RomieuG,MathieuA, 2014.HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort,Cancer Med 3 134 -42
FerrettiG,FeliciA,PapaldoP,FabiA,CognettiF., 2007.HER2/neu role in breast cancer: From a prognostic foe to a predictive friend,Cur Opin Obstet Gynecol 19 56 -62
PerezEA,RomondEH,SumanVJ,JeongJH,SledgeG,Geyer JrCE,NCCTGN9831. J Clini, 2014.Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31, 32 3744 -52
BuzdarAU,IbrahimNK,FrancisD,BooserDJ,ThomasES,TheriaultRL, 2005.Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer,J Clin Oncol 23 3676 -85
GianniL,EiermannW,SemiglazovV,LluchA,TjulandinS,ZambettiM, 2014.Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort,Lancet Oncol 15 640 -7
BroglioKR,QuintanaM,FosterM,OlingerM,McGlothlinA,BerrySM, 2016.Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis,JAMA Oncol 2 751 -60
SpringL,GreenupR,ReynoldsK,SmithBL,MoyB,BardiaA, 2016.Pathological complete response after neoadjuvant chemotherapy predicts improved survival in all major subtypes of breast cancer: systematic review and meta-analyses of over 18,000 patients. 2016 AACR Annual Meeting,Abstract presented April 18 -
ProwellTM,PazdurR, 2012.Pathological complete response and accelerated drug approval in early breast cancer,New Engl J Med 366 2438 -41
CortazarP,ZhangL,UntchM,MehtaK,CostantinoJP,WolmarkN, 2014.Pathological complete response and longterm clinical benefit in breast cancer: the CTNeoBC pooled analysis,Lancet 384 164 -72
UntchM,RezaiM,LoiblS,FaschingPA,HuoberJ,TeschH, 2010.Neoadjuvant treatment with trastuzumab in HER2- positive breast cancer: Results from the GeparQuattro study,J Clin Oncol 28 2024 -31
UntchM,FaschingPA,KonecnyGE,HasmüllerS,LebeauA,KreienbergR, 2011.Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups,J Clin Oncol 29 3351 -7
GianniL,EiermannW,SemiglazovV,ManikhasA,LluchA,TjulandinS, 2010.Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2- positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2- negative cohort,Lancet 375 377 -84
ZeeshanS,KhanSM,KhanN., 2016.Pathologic tumor response and long term outcome with neoadjuvant trastuzumab in Her-2 positive breast cancer,Ann Oncol 27 006 -
GajriaD,ChandarlapatyS., 2011.HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies,Expert Rev Anticancer Ther 11 263 -75
SternHM,GardnerH,BurzykowskiT,ElatreW,O'BrienC,LacknerMR, 2015.PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance,Clin Cancer Res 21 2065 -74